Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma
Expert Opin Pharmacother. 2024 Apr 12. doi: 10.1080/14656566.2024.2342403. Online ahead of print.ABSTRACTINTRODUCTION: Increasing evidence from preclinical and clinical studies suggests the role of vascular endothelial growth factor (VEGF) signaling in melanoma progression, response to therapy, and overall survival. Moreover, the discovery of the potential involvement of the VEGF pathway in resistance to immunotherapy has led to new clinical trials with VEGFR inhibitors.AREAS COVERED: We have reviewed recent literature, mainly published within the last 5 years, on VEGFR-targeted treatments for advanced melanoma, including ...
Source: Expert Opinion on Pharmacotherapy - April 12, 2024 Category: Drugs & Pharmacology Authors: Pawe ł Sobczuk Micha ł Cholewiński Piotr Rutkowski Source Type: research
Current challenges with adherence to pharmacotherapy in allergic rhinitis
Expert Opin Pharmacother. 2024 Apr 11:1-4. doi: 10.1080/14656566.2024.2336082. Online ahead of print.NO ABSTRACTPMID:38602452 | DOI:10.1080/14656566.2024.2336082 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 11, 2024 Category: Drugs & Pharmacology Authors: Yuan Zhang Luo Zhang Source Type: research
Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond
Expert Opin Pharmacother. 2024 Apr 9:1-15. doi: 10.1080/14656566.2024.2339926. Online ahead of print.ABSTRACTINTRODUCTION: Despite the growing number of highly efficacious biologics and chemical drugs for ulcerative colitis (UC), steroid-free disease control is still difficult to achieve in subgroups of patients due to refractoriness, adverse events, primary or secondary failure. New treatments are therefore still required in order to optimize clinical management of patients with UC.AREAS COVERED: The efficacy and safety of both currently available and newly developed small molecules have been summarized. The PubMed databa...
Source: Expert Opinion on Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Benedetto Neri Roberto Mancone Mariasofia Fiorillo Sara Concetta Schiavone Elena De Cristofaro Stefano Migliozzi Livia Biancone Source Type: research
Emerging therapies targeting growth factors in hepatocellular carcinoma
Expert Opin Pharmacother. 2024 Apr 9:1-8. doi: 10.1080/14656566.2024.2340714. Online ahead of print.ABSTRACTINTRODUCTION: Hepatocellular carcinoma (HCC) is a primary liver cancer that commonly arises in the background of chronic liver inflammation and/or cirrhosis. Chronic liver inflammation results in the production of different growth factors, remodeling of the microenvironment architecture into fibrosis, and eventually carcinogenesis. Overexpression of some growth factors has been associated with worse prognosis in patients with HCC. Targeted therapies against growth factors may disrupt cell signaling and the mechanisms...
Source: Expert Opinion on Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Samantha M Ruff Timothy M Pawlik Source Type: research
Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond
Expert Opin Pharmacother. 2024 Apr 9:1-15. doi: 10.1080/14656566.2024.2339926. Online ahead of print.ABSTRACTINTRODUCTION: Despite the growing number of highly efficacious biologics and chemical drugs for ulcerative colitis (UC), steroid-free disease control is still difficult to achieve in subgroups of patients due to refractoriness, adverse events, primary or secondary failure. New treatments are therefore still required in order to optimize clinical management of patients with UC.AREAS COVERED: The efficacy and safety of both currently available and newly developed small molecules have been summarized. The PubMed databa...
Source: Expert Opinion on Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Benedetto Neri Roberto Mancone Mariasofia Fiorillo Sara Concetta Schiavone Elena De Cristofaro Stefano Migliozzi Livia Biancone Source Type: research
Emerging therapies targeting growth factors in hepatocellular carcinoma
Expert Opin Pharmacother. 2024 Apr 9:1-8. doi: 10.1080/14656566.2024.2340714. Online ahead of print.ABSTRACTINTRODUCTION: Hepatocellular carcinoma (HCC) is a primary liver cancer that commonly arises in the background of chronic liver inflammation and/or cirrhosis. Chronic liver inflammation results in the production of different growth factors, remodeling of the microenvironment architecture into fibrosis, and eventually carcinogenesis. Overexpression of some growth factors has been associated with worse prognosis in patients with HCC. Targeted therapies against growth factors may disrupt cell signaling and the mechanisms...
Source: Expert Opinion on Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Samantha M Ruff Timothy M Pawlik Source Type: research
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy
Expert Opin Pharmacother. 2024 Apr 8. doi: 10.1080/14656566.2024.2340738. Online ahead of print.ABSTRACTINTRODUCTION: Chimeric antigen receptor (CAR) T cells have revolutionized treatment of multiple hematologic malignancies. Engineered cellular therapies now offer similar hope to transform management of solid tumors and autoimmune disease. However, toxicities can be serious and often require hospitalization.AREAS COVERED: We review the two chief toxicities of CAR T therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and the rarer immune effector cell-associated hemo...
Source: Expert Opinion on Pharmacotherapy - April 8, 2024 Category: Drugs & Pharmacology Authors: Zandra E Walton Matthew J Frigault Marcela V Maus Source Type: research
Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan
CONCLUSIONS: The anticipated association between AI exposure and osteoporotic fracture risk in Japanese women with breast cancer was not seen clearly.PMID:38588537 | DOI:10.1080/14656566.2024.2340712 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 8, 2024 Category: Drugs & Pharmacology Authors: Tetsuya Taguchi Hisashi Matsushima Sho Kodama Naoki Okubo Tetsuo Ito Maja Ludwikowska Seiji Fukumoto Toshio Matsumoto Source Type: research
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy
Expert Opin Pharmacother. 2024 Apr 8. doi: 10.1080/14656566.2024.2340738. Online ahead of print.ABSTRACTINTRODUCTION: Chimeric antigen receptor (CAR) T cells have revolutionized treatment of multiple hematologic malignancies. Engineered cellular therapies now offer similar hope to transform management of solid tumors and autoimmune disease. However, toxicities can be serious and often require hospitalization.AREAS COVERED: We review the two chief toxicities of CAR T therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and the rarer immune effector cell-associated hemo...
Source: Expert Opinion on Pharmacotherapy - April 8, 2024 Category: Drugs & Pharmacology Authors: Zandra E Walton Matthew J Frigault Marcela V Maus Source Type: research
Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan
CONCLUSIONS: The anticipated association between AI exposure and osteoporotic fracture risk in Japanese women with breast cancer was not seen clearly.PMID:38588537 | DOI:10.1080/14656566.2024.2340712 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 8, 2024 Category: Drugs & Pharmacology Authors: Tetsuya Taguchi Hisashi Matsushima Sho Kodama Naoki Okubo Tetsuo Ito Maja Ludwikowska Seiji Fukumoto Toshio Matsumoto Source Type: research
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Expert Opin Pharmacother. 2024 Apr 3:1-12. doi: 10.1080/14656566.2024.2336069. Online ahead of print.ABSTRACTINTRODUCTION: Available treatments for colorectal cancer are limited. However, in the last few years several advances and new treatment options became available and expanded the continuum of care in metastatic colorectal cancer (mCRC).AREAS COVERED: Fruquintinib, a tyrosine kinase inhibitor, has been shown to be effective in heavily pretreated mCRC progressing to trifluridine-tipiracil (FTD/TPI) or regorafenib or both. Preclinical studies have shown that fruquintinib inhibits with high selectivity VEGFR 1-2-3, leadi...
Source: Expert Opinion on Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Erika Stucchi Michela Bartolini Marco Airoldi Roberta Fazio Valentina Dapr à Giuseppe Mondello Maria Giuseppina Prete Alberto Puccini Armando Santoro Source Type: research
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
CONCLUSION: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.PMID:38568074 | DOI:10.1080/14656566.2024.2337261 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Elif Şenocak Taşçı Yasin Kutlu Ömer Fatih Ölmez Arda Ula ş Mutlu Yasemin G ündoğdu Mustafa Seyyar Elif Şahin Devrim Çabuk Nargiz Majidova İrem Uğurlu Ay şe Demirci Din çer Aydın Ey üp Çavdar Selami Bayram Nilg ün Yıldırım Fatih Karat Source Type: research
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Expert Opin Pharmacother. 2024 Apr 3:1-12. doi: 10.1080/14656566.2024.2336069. Online ahead of print.ABSTRACTINTRODUCTION: Available treatments for colorectal cancer are limited. However, in the last few years several advances and new treatment options became available and expanded the continuum of care in metastatic colorectal cancer (mCRC).AREAS COVERED: Fruquintinib, a tyrosine kinase inhibitor, has been shown to be effective in heavily pretreated mCRC progressing to trifluridine-tipiracil (FTD/TPI) or regorafenib or both. Preclinical studies have shown that fruquintinib inhibits with high selectivity VEGFR 1-2-3, leadi...
Source: Expert Opinion on Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Erika Stucchi Michela Bartolini Marco Airoldi Roberta Fazio Valentina Dapr à Giuseppe Mondello Maria Giuseppina Prete Alberto Puccini Armando Santoro Source Type: research
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
CONCLUSION: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.PMID:38568074 | DOI:10.1080/14656566.2024.2337261 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Elif Şenocak Taşçı Yasin Kutlu Ömer Fatih Ölmez Arda Ula ş Mutlu Yasemin G ündoğdu Mustafa Seyyar Elif Şahin Devrim Çabuk Nargiz Majidova İrem Uğurlu Ay şe Demirci Din çer Aydın Ey üp Çavdar Selami Bayram Nilg ün Yıldırım Fatih Karat Source Type: research
